Author:
Vanderpuye-Orgle Jackie,Erim Daniel,Qian Yi,Boyne Devon J.,Cheung Winson Y.,Bebb Gwyn,Shah Ariel,Pericleous Louisa,Maruszczak Maciej,Brenner Darren R.
Publisher
Springer Science and Business Media LLC
Reference66 articles.
1. Organisation for Economic Co-operation and Development. Pharmaceutical spending. 2021. https://data.oecd.org/healthres/pharmaceutical-spending.htm. Accessed 10 Aug 2021.
2. Gotfrit J, Shin JJW, Mallick R, Stewart DJ, Wheatley-Price P. Potential life-years lost: the impact of the cancer drug regulatory and funding process in Canada. Oncologist. 2020;25(1):e130–7.
3. Millson B, Thiele S, Zhang Y, Dobson-Belaire W, Skinner B. Access to new medicines in public drug plans: Canada and comparable countries. 2016 annual report. 2016. http://innovativemedicines.ca/wp-content/uploads/2016/05/20160524_Access_to_Medicines_Report_EN_Web.pdf. Accessed 10 Aug 2021.
4. Salek S, Lussier Hoskyn S, Johns JR, Allen N, Sehgal C. Factors influencing delays in patient access to new medicines in Canada: a retrospective study of reimbursement processes in public drug plans. Front Pharmacol. 2019;10(196). https://doi.org/10.3389/fphar.2019.00196.
5. Rawson NSB. Has pCODR improved access to oncology drugs? Timeliness and provincial acceptance of pan-Canadian Oncology Drug Review recommendations. 2014. https://www.fraserinstitute.org/sites/default/files/has-pCODR-improved-access-to-oncology-drugs-rev.pdf. Accessed 12 Aug 2021.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献